Clinical trial data from the SURMOUNT-1 study showed that gastrointestinal adverse events were significantly more common during dose escalation periods (Jastreboff et al., 2022, NEJM)
Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System, Sikiric P, Seiwerth S, Skrtic A, Staresinic M, Strbe S, Vuksic A, Sikiric S, Bekic D, Soldo D, Grizelj B, Novosel L, Beketic Oreskovic L, Oreskovic I, Stupnisek M, Boban Blagaic A, Dobric I, Pharmaceuticals (Basel), Pharmaceuticals, 2025 Jun 19;18(6):928
This report provides a realistic, fact-based explanation without overstating claims or promoting non-approved uses." What the 2026 Report Reveals About AOD-9604 As explained in the new analysis, AOD-9604 is a lipolytic fragment and modified peptide derived from the C-terminus of human growth hormone (HGH), originally developed to explore mechanisms related to fat metabolism, lipolysis, and how the body may burn fat or influence fat cells without affecting growth hormone levels
Frontiers in Pharmacology, 11, 627533
MIC (Methionine, Inositol, Choline) These specific Lipotropic nutrients are amino acids in the body that play a role in the breakdown and metabolism/removal of fat from the liver
